[The present state and problems of HCV blood screening system in blood products].
After discovering HCV antibody in 1989, the new cases of posttransfusion hepatitis C has been rare. This HCV antibody screening system provided certainly the powerful preventive effect from HCV infection through blood products. But it was possible to infect HCV through the blood products without HCV antibody but with HCV-RNA. This phenomenon seemed to be observed in a window period between time at infection and antibody appearance. To detect the infectious source at a window period in blood products, NAT(nucleic acid amplification) method was adapted recently in Japanese red cross. For safe blood screening system, continuous efforts such as NAT will be needed forever.
Yatsuhashi
H
H
Institute for Clinical Research, Nagasaki Chuo National Hospital.
Yano
M
M
D015415:Biomarkers / Q000032:analysis; D001782:Blood Donors; D001802:Blood Substitutes; D001803:Blood Transfusion; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000175:diagnosis* / Q000517:prevention & control / Q000635:transmission; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D007564:Japan; D021141:Nucleic Acid Amplification Techniques; D012367:RNA, Viral / Q000032:analysis; D012011:Red Cross; D013997:Time Factors
D015415:Biomarkers; D001802:Blood Substitutes; D018937:Hepatitis C Antibodies; D012367:RNA, Viral